Thinly traded nano cap Baudax Bio (NASDAQ:BXRX) is up 11% premarket on light volume on the heels of its announcement that the FDA’s action date is Thursday, February 20, for its review of its marketing application for intravenous (IV) meloxicam for the management of moderate-to-severe pain.
The company was spun out from Recro Pharma last year after the FDA rejected its IV meloxicam application a second time.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.